{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:08:29Z","timestamp":1783573709385,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3533,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1093\/annonc\/mdp514","type":"journal-article","created":{"date-parts":[[2009,11,11]],"date-time":"2009-11-11T20:50:47Z","timestamp":1257972647000},"page":"759-765","source":"Crossref","is-referenced-by-count":23,"title":["Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes"],"prefix":"10.1016","volume":"21","author":[{"given":"S.","family":"Pecorelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Tredan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Parma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Katsar\u00f2s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lhomm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Lissoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.","family":"Vermorken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Frigerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Carminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Brienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Guastalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp514_bb0010","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1093\/annonc\/mdp514_bb0015","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdp514_bb0020","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1093\/annonc\/mdp514_bb0025","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCI CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdp514_bb0030","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1200\/JCO.2005.09.032","article-title":"Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails","volume":"23","author":"Sessa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp514_bb0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mdl418","article-title":"Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors","volume":"18","author":"Sessa","year":"2007","journal-title":"Ann Oncol"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mdp514_bb0040","doi-asserted-by":"crossref","first-page":"viii20","DOI":"10.1093\/annonc\/mdi963","article-title":"Clinical trials in ovarian carcinoma: study methodology","volume":"16","author":"Vermorken","year":"2005","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdp514_bb0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"10.1093\/annonc\/mdp514_bb0050","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdp514_bb0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"10.1093\/annonc\/mdp514_bb0060","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2004.06.628","article-title":"Can we now agree to use the same definitions to measure response according to CA-125?","volume":"22","author":"Rustin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp514_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdp514_bb0070","unstructured":"Topotecan Summary of Product Characteristics http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/hycamtin\/hycamtin.htm(21 October 2009, date last accessed)"},{"key":"10.1093\/annonc\/mdp514_bb0075","unstructured":"Irinotecan Prescribing Information, revised July 2008 http:\/\/www.pfizer.com\/files\/products\/uspi_camptosar.pdf (21 October 2009, date last accessed)"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mdp514_bb0080","first-page":"viii1","article-title":"A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer","volume":"19","author":"Monk","year":"2008","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1093\/annonc\/mdp514_bb0085","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analogue, in patients with taxane-resistant metastatic breast cancer","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419389513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419389513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/4\/759\/366989\/mdp514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:21:31Z","timestamp":1624504891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419389513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0923753419389513"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp514","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1189956.654054","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}